ArticleFrontiers in medicine2026
Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to comprehensively analyze the adverse events associated with neuraminidase inhibitor (NAI) use in pregnant women in real-world clinical settings, providing a valuable reference for the management of anti-influenza treatment in this population. Methods: The study extracted data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2025. Signal detection was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) methods. Adverse events (AEs) were classified according to the system organ class (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA) version 27.0. Results: From Q1 2004 to Q3 2025, a total of 3,687 ADE reports were retrieved in this study, including 3,211 reports for oseltamivir, 471 reports for zanamivir, and 5 reports for peramivir. For oseltamivir, significant AEs at SOCs were injury, poisoning, and procedural complications; pregnancy, puerperium, and perinatal conditions; and general disorders and administration site conditions. The five strongest AE signals were proctitis, infantile acne, congenital intestinal obstruction, no adverse event, and placental necrosis. For zanamivir, significant AEs at SOCs were injury, poisoning, and procedural complications; pregnancy, puerperium, and perinatal conditions; and respiratory, thoracic, and mediastinal disorders. The five strongest AE signals were delivery, bronchospasm, pneumothorax, exposure during pregnancy, and product quality issue. Conclusion: The study findings align with current guidelines recommending neuraminidase inhibitors as the primary antiviral treatment of pregnant women with influenza. Our study may offer valuable evidence to support the clinical use of neuraminidase inhibitors, particularly in identifying adverse events and ensuring their safe administration in women during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.